RRx-001

DB12060InvestigationalSmall molecule

RRx-001 has been used in trials studying the treatment of Lymphomas, Brain Metastases, Cholangiocarcinoma, Colorectal Neoplasms, and Malignant Solid Tumor, among others.

Mechanism: Pharmacologically active on Peroxisome proliferator-activated receptor gamma, Glucose-6-phosphate 1-dehydrogenase, and Myc proto-oncogene protein
Curator reviewed
Formula / weight: C₅H₆BrN₃O₅ · 268.023 g/mol (avg)
Also known as: N-(Bromoacetyl)-3,3-Dinitroazetidine
Code names: RRx-001

Resolves to

Compound

UNII7RPW6SU9SCCAS925206-65-1ChEMBLCHEMBL3526802PubChem15950826

Structure

InChIKeyJODKFOVZURLVTG-UHFFFAOYSA-NSMILES[O-][N+](=O)C1(CN(C1)C(=O)CBr)[N+]([O-])=O

Targets

P37231PPARGP11413G6PDP01106MYCQ16236NFE2L2Q96P20NLRP3

What you can answer from here — as of July 07, 2026

5Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

14Clinical trialsPhase, status and sponsor resolved per trial

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with RRx-001, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account